Precipio, Inc. Q2 2026 Earnings: Revenue Beats $7.02 Million Record
Precipio (NASDAQ: PRPO) reported Q2 2026 GAAP EPS of -$0.12 and a GAAP net loss of $0.219 million, alongside record net sales of $7.02 million, up about 24% year over year. Revenue beat the cited consensus $1.68 million. Product revenue rose to $0.906 million and adjusted EBITDA was $0.4 million. Cash at quarter-end was $3.08 million.
How this was made
The 30-second read
Why it matters
Q2 shows record sales, margin expansion, and positive adjusted EBITDA, but GAAP remains negative and the 10-Q includes going-concern doubt, creating a two-sided setup for traders.
Market read
Traders can reassess near-term fundamentals based on the revenue and adjusted EBITDA beat, while monitoring balance-sheet durability given going-concern disclosure and lack of forward guidance.
What to watch
No quantified Q3 or full-year guidance was provided, and the cash-flow discussion notes ERC receipts helped over the prior 18 months, which may not be repeatable.
Background
Precipio operates a CLIA pathology lab network and develops proprietary diagnostic products, aiming to blend service revenue with product commercialization.
Ticker impact
Precipio reported Q2 2026 record net sales of $7.02M, beating consensus, with GAAP EPS of -$0.12 and positive adjusted EBITDA.
Near-term bias modestly positive, with volatility risk from going-concern language and lack of quantified Q3/full-year guidance.
The article provides concrete Q2 financial beats (revenue and adjusted EBITDA) plus cash balance improvement, but also highlights GAAP losses and explicit going-concern doubt, which can cap upside and drive swings.
Market effects
Adds datapoint on profitability trajectory for specialty cancer diagnostics and lab-service hybrids, but limited broader sector signal.
No clear regional spillover beyond US small-cap healthcare diagnostics.
Primarily company-specific; no international regulatory or commercial expansion details.
Counterpoint
The revenue beat may be partly offset by non-recurring items and GAAP losses, while going-concern language can dominate valuation despite adjusted improvements.
Key entities
- companyPrecipio, Inc.
NASDAQ-listed specialty cancer diagnostics and healthcare biotechnology company reporting Q2 2026 results.
- personIlan Danieli
CEO quoted on Q2 momentum and cash generation without a financing event.
